



Eradicating disease through capital investment

26 November 2018

Announcements

National Stock Exchange of Australia
PO Box 283
Newcastle NSW 2300

Market Announcement – 2018 Annual General Meeting Chairman Opening Address

A copy of opening address which being presented by Mr Kos Dimitriou (Chairman) is attached. The opening address is being presented at 9:30am on 26 November 2018, at the Annual General Meeting of iQX Limited, which is being held at the Grace Hotel, Sydney.

Sincerely

Gerardo Incollingo
Company Secretary

Chairman's opening address

On behalf of the board of directors, it is an honour and privilege to provide a review of iQX Limited for the financial year ended 30 June 2018.

The iQX team has successfully continued to translate the Company's strategy, into tangible deliverables including:

- The realisation of good value investment at the early stage; and
- The expansion of our infrastructure, in particular the establishment of Capital Labs, the equity crowd sourcing business unit of iQX Limited subsidiary, iQX Investment Services Pty Limited. The financial results for the year ended 30 June 2018 reflect the on-going investment and development of iQX Limited's early stage biotechnology assets.

iQX Limited is always seeking to deliver value to all its stakeholders and to ensure that we partner with the iQ Group of companies to identify and invest into sustainable early stage biotechnology investments, on a global scale in order to continue the journey of eradicating disease through capital investment.

We are confident that our entrepreneurial, curious and innovative iQX team, led by an aspirational and committed group of executive management and board members, can deliver on the clear mandate to build the iQX business and make a real difference within the Australian Life Science sector.